Threshold New Data on Combination of TH-302 and Avastin in Recurrent Glioblastoma to be Presented at WFNO/SNO

Threshold Pharmaceuticals

today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of its investigational hypoxia-targeted drug TH-302 and Avastin® (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure (Study 4003) will be presented at the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting held in conjunction with the 18th annual 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO). The 2013 WFNO/SNO meeting will take place November 21-24, San Francisco, CA. The related poster presentation is scheduled for Friday November 22, 2013, 7:00 PM - 9:00 PM Pacific Time at the 2013 WFNO/SNO meeting.